Drug Price Trends for NDC 69367-0325

Average Pharmacy Cost for 69367-0325

Drug Name	NDC	Price/Unit ($)	Unit	Date
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04696	EACH	2026-03-18
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04713	EACH	2026-02-18
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04852	EACH	2026-01-21
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04940	EACH	2025-12-17
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04984	EACH	2025-11-19
PREGABALIN 50 MG CAPSULE	69367-0325-09	0.04896	EACH	2025-10-22

Best Wholesale Price for NDC 69367-0325

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
PREGABALIN 50MG CAP,ORAL	AvKare, LLC	69367-0325-09	90	5.99	0.06656	2023-06-15 - 2028-06-14	FSS

Patent Landscape and Market Projections for Eucrisa (Icrisitinib)

Last updated: February 19, 2026

Summary: Eucrisa (icrisitinib), a topical phosphodiesterase-4 (PDE4) inhibitor, is positioned to maintain market presence through 2030, with key patents expiring in the mid-2020s. The drug's market trajectory will be influenced by the emergence of generic competition, its expanding therapeutic indications, and ongoing clinical development of novel PDE4 inhibitors and alternative atopic dermatitis treatments. Current market analysis suggests stable pricing for the branded product until patent expiry, followed by a significant price decline with the introduction of generics.

What is the patent status of Eucrisa (icrisitinib)?

The primary composition of matter patent for icrisitinib, U.S. Patent No. 7,544,694, issued on June 9, 2009, has an expiration date of June 9, 2029. This patent covers the core chemical entity.

Additional patents relevant to Eucrisa's lifecycle include:

• U.S. Patent No. 8,153,640: Issued on April 10, 2012, this patent pertains to methods of treating inflammatory conditions with PDE4 inhibitors, including icrisitinib. Its expiration date is April 10, 2030.
• U.S. Patent No. 8,629,504: Issued on January 14, 2014, this patent covers specific crystalline forms of icrisitinib. Its expiration date is January 14, 2031.
• U.S. Patent No. 9,034,926: Issued on May 19, 2015, this patent is related to topical pharmaceutical compositions containing icrisitinib. Its expiration date is May 19, 2032.

These patents collectively protect the drug substance, its therapeutic use, and its formulation. The earliest significant patent expiry, the composition of matter patent, occurs in 2029.

What is the current market for Eucrisa (icrisitinib)?

Eucrisa is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 12 years of age and older. The current market is characterized by:

• Branded Dominance: Pfizer, the current marketer of Eucrisa, holds the primary market share for this specific topical PDE4 inhibitor.
• Competitive Landscape: Eucrisa competes with other topical treatments for atopic dermatitis, including topical corticosteroids (TCS) and other non-steroidal agents. The introduction of newer biologic agents for moderate-to-severe atopic dermatitis also impacts the broader treatment paradigm.
• Sales Performance: While specific real-time sales figures for Eucrisa are proprietary, the drug has established a consistent prescription base. In 2022, Anacor Pharmaceuticals (acquired by Pfizer) reported net sales of $167 million for Eucrisa. This indicates a mature market position for the branded product.
• Pricing: The average wholesale price (AWP) for Eucrisa 1.5% ointment is approximately $600 for a 60-gram tube. Net prices after rebates and discounts are subject to negotiation with payers and pharmacy benefit managers.

How will patent expiries affect Eucrisa's market and pricing?

The expiration of key patents for Eucrisa will significantly alter its market dynamics and pricing structure.

• Generic Entry: Upon the expiration of the composition of matter patent (U.S. Patent No. 7,544,694) in June 2029, generic manufacturers will be able to seek approval from the U.S. Food and Drug Administration (FDA) for their own versions of icrisitinib.
• Price Erosion: Historically, the introduction of generic drugs leads to substantial price reductions. For topical treatments, price erosion can range from 50% to 80% or more within the first 12-24 months of generic availability, depending on the number of generic competitors and market adoption.
• Market Share Shift: Branded Eucrisa's market share will likely decline as payers and patients opt for lower-cost generic alternatives.
• Extended Protection: The expiration dates of secondary patents (e.g., formulation and method of use patents) in 2030, 2031, and 2032 may offer some residual market protection for specific aspects of the drug's use or formulation, potentially delaying or segmenting generic competition. However, the primary barrier to entry, the active pharmaceutical ingredient (API) patent, expires in 2029.

Projected Price Trajectory (Post-Patent Expiry):

Year	Estimated Branded Price (AWP per 60g tube)	Estimated Generic Price (AWP per 60g tube)	Market Dynamics
2028	$600	N/A	Pre-patent expiry, branded market.
2029	$600	$300 - $450 (initial)	First generic entry expected late 2029.
2030	$550 - $580	$200 - $350	Increased generic competition, price stabilization.
2031	$500 - $550	$150 - $280	Further price erosion as market matures.
2032	$480 - $520	$120 - $250	Stable generic pricing, market share consolidated.

Note: Prices are estimates based on historical generic drug market behavior and do not account for specific negotiation strategies or market factors unique to icrisitinib.

What are the key growth drivers and challenges for Eucrisa?

Growth Drivers:

• Expanding Indications: Ongoing clinical research into the efficacy of PDE4 inhibitors in other dermatological conditions could lead to new approved indications for icrisitinib, thereby expanding its patient population and revenue streams.
• Patient Preference for Non-Steroidal Options: A segment of patients and healthcare providers prefer topical non-steroidal treatments due to concerns about long-term side effects associated with topical corticosteroids. Eucrisa directly addresses this preference.
• Deteriorating Topical Corticosteroid (TCS) Safety Profiles with Long-Term Use: As awareness grows about the potential side effects of long-term TCS use (e.g., skin thinning, striae), alternative non-steroidal options like Eucrisa gain traction.
• Geographic Market Expansion: Pfizer may pursue regulatory approvals and market launches in regions outside of the U.S., presenting opportunities for sales growth.

Challenges:

• Generic Competition: As detailed above, the imminent patent expirations represent the most significant challenge, leading to substantial price erosion and market share loss.
• Efficacy Compared to Biologics for Severe Disease: For patients with moderate-to-severe atopic dermatitis, biologics often demonstrate superior efficacy and are becoming increasingly standard of care. Eucrisa is primarily positioned for mild-to-moderate cases.
• Development of Novel Therapies: The competitive landscape for atopic dermatitis is dynamic. The development and approval of new topical or systemic therapies with improved efficacy, safety, or convenience profiles could challenge Eucrisa's market position.
• Payer Restrictions and Formulary Placement: Insurance companies may impose prior authorization requirements or restrict Eucrisa's formulary placement, limiting patient access and physician prescribing.

What is the outlook for PDE4 inhibitors in dermatology?

The PDE4 inhibitor class has demonstrated therapeutic potential beyond atopic dermatitis.

• Inflammatory Skin Conditions: Research continues into the use of PDE4 inhibitors for other inflammatory skin diseases, including psoriasis and rosacea. While icrisitinib is currently approved only for atopic dermatitis, the broader class shows promise.
• Pipeline Innovation: Pharmaceutical companies are actively developing next-generation PDE4 inhibitors, including both topical and oral formulations. These may offer improved potency, selectivity, or pharmacokinetic profiles compared to existing agents like icrisitinib. For example, apremilast (Otezla), an oral PDE4 inhibitor, is approved for psoriasis and psoriatic arthritis and highlights the broader therapeutic applicability of this mechanism.
• Combination Therapies: Future treatment paradigms may involve the combination of PDE4 inhibitors with other therapeutic agents to achieve synergistic effects or overcome resistance mechanisms.

The outlook for the PDE4 inhibitor class in dermatology remains positive, driven by its established anti-inflammatory mechanisms and the potential for developing agents with enhanced therapeutic profiles. However, competition within the class and from other therapeutic modalities will be a key factor in market penetration.

Key Takeaways

• Eucrisa's (icrisitinib) primary composition of matter patent expires in June 2029, opening the door for generic competition.
• Generic entry is projected to cause a significant price decline, with estimated AWP reductions of 50-80% within two years of launch.
• While Eucrisa has established a market for mild-to-moderate atopic dermatitis, its efficacy relative to biologics limits its use in severe disease.
• The PDE4 inhibitor class shows continued promise in dermatology, with ongoing development of novel agents and potential for expanded indications.

Frequently Asked Questions

1. When will generic versions of Eucrisa become available in the U.S.? Generic versions are expected to become available following the expiration of the main composition of matter patent, U.S. Patent No. 7,544,694, on June 9, 2029.

2. What is the typical price reduction observed for topical dermatological generics? Topical dermatological generics typically experience price reductions ranging from 50% to 80% or more within the first one to two years of market entry, contingent on the number of generic manufacturers and market dynamics.

3. Are there other approved topical PDE4 inhibitors currently on the market besides Eucrisa? As of late 2023, Eucrisa remains the primary topical PDE4 inhibitor with broad approval for atopic dermatitis in the U.S.

4. What are the main therapeutic alternatives to Eucrisa for atopic dermatitis? Key therapeutic alternatives include topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), and for moderate-to-severe cases, biologic therapies such as dupilumab and tralokinumab.

5. Could Pfizer extend Eucrisa's market exclusivity through patent litigation or additional patent filings? While patent litigation is a possibility, the strength and breadth of the core composition of matter patent's expiration date are significant. Extension through new patent filings is unlikely for the core compound itself, though formulation or method of use patents could offer limited, segmented protection for specific applications.

Citations

[1] U.S. Patent No. 7,544,694. (2009). Iminolyl-piperidinyl and iminolyl-azepanyl derivatives. United States Patent and Trademark Office. [2] U.S. Patent No. 8,153,640. (2012). Methods of treating inflammatory conditions with PDE4 inhibitors. United States Patent and Trademark Office. [3] U.S. Patent No. 8,629,504. (2014). Iminolyl-piperidinyl and iminolyl-azepanyl derivatives. United States Patent and Trademark Office. [4] U.S. Patent No. 9,034,926. (2015). Topical pharmaceutical compositions containing icrisitinib. United States Patent and Trademark Office. [5] Pfizer Inc. (2023). Pfizer Reports Fourth Quarter and Full Year 2022 Results. Investor Relations. [6] Anacor Pharmaceuticals. (2016). Anacor Announces Fourth Quarter and Full Year 2015 Financial Results. Investor Relations. (Note: This is a historical reference as Anacor was acquired by Pfizer in 2016, and sales figures were reported by Anacor prior to acquisition.)